Men can check for estrogen dominance and hyperaromatization markers such as strawberry dots on the tongue (Figure 1) or cherry angiomas, which can be located on the torso (Figure 2) or the forehead (Figure 3). All these are signs of excess estrogen. Strawberry dots on the tongue and cherry angiomas on the torso indicate hyperaromatization and a risk for prostate issues. If the cherry angiomas are located on the forehead, there is a risk for stroke or aneurysm. This risk is 8 times higher if you have hypertension or a family history of stroke or aneurysm. Check your C-Reactive Protein (CRP) and homocysteine levels to further determine your stroke/aneurysm risk. A CRP above 1.0 is considered at risk for cardiovascular disease. Homocysteine should be around 6.



You can also look for symptoms of estrogen dominance, such as:

• Belly fat
• Low libido
• Reduced muscle tone
• Gynecomastia (male breast enlargement)

Men can also check their PSA, the prostate specific antigen, a marker for prostate cancer. Ideally, PSA level should be under 1. For men under 50, it should be less than 0.68. For men under 55, it should be under 0.85. For men over 75, it should be less than 2.5 (Table 2).










It is important to keep PSA level in check because studies show that higher PSA levels are associated with higher rates of prostate cancer mortality. For instance, men between 45 and 49 with PSA levels over 1.6 and men between age 51 and 55 with PSA over 2.4 have the highest mortality (Table 3) (British Medical Journal. 2013;346: f325).










Prostate tissue is estrogen-responsive and the prostate can increase in size with estrogenic stimulation. So men should be aware of this, especially if they have high PSA, a history of prostate disease in the family or if they are on testosterone therapy. Testosterone converts to estrogen and contributes to estrogenic stimulation of the prostate.

Did you know that we all have microscopic cancers just waiting to grow? About 50% of men between 50 and 60 years old have microscopic prostate cancers. So any estrogen stimulation can trigger the growth of these microscopic tumors. Growth factors can also trigger new blood vessels to form, feed these microscopic cancers and make them grow.

To lower PSA, taking Myomin and Prosta Chi is recommended. For high PSA, especially if you have signs of an enlarged prostate, add Angiostop to avoid microscopic prostate tumors from growth.


HORMONE THERAPY AND PROSTATE CANCER RISK 

For men on testosterone therapy, the risk for prostate cancer increases. Studies show that testosterone alone induced prostate cancer by 40%. Adding estradiol induced prostate cancer by 100% (Table 4)! (Exp Rev Endocrinol & Metab. 2011; 6(3): 437-451; J Clin Endocrinol. Metab. 2011; 92(7):2519–2525). For men who are already estrogen-dominant, then the risk is only amplified. So it is important to watch for signs of estrogen dominance. If you do, check your PSA, estradiol and testosterone levels (refer to Tables 1 and 2 for ideal levels).

It is also important to remember that aromatase expression is 30 times higher in metastatic prostate cancer tissues (Cancer Res. 2008; 68:4447–4454; FASEB J.22, 1512–1520 (2008). And those with higher estradiol levels, like African American men, have a twice higher risk of prostate cancer (J Clin Endocrinol Metab. 2007; Endocrinology. 2011;152 (6):2150-63).

TESTOSTERONE LOW DESPITE HRT/BHRT


Some men on testosterone therapy may wonder why their testosterone level is still below ideal levels. Looking at the biochemical pathway of hormones (Figure 4), testosterone can be aromatized to estradiol or converted to DHT (dihydrotestosterone) through the 5-alpha reductase enzyme. It wouldn’t matter how much testosterone is taken. If hyperaromatization occurs, testosterone is readily turned into estradiol and will always be deficient. Or it could be converted to its more potent form DHT. Correcting this problem is easy. Block the aromatase enzyme with Myomin in order to build up more testosterone. And block the 5-alpha reductase enzyme with Prosta Chi so it is not converted to DHT.

For men who have low testosterone, high estradiol and high PSA, take Myomin immediately. It will reduce the expression of aromatase, minimizing this conversion of testosterone to estradiol. As a result, estradiol will reduce and testosterone will increase. PSA will also reduce. Men on testosterone, or even DHEA therapy, should add Myomin to block the unwanted conversion of these hormones to estrogen, leaving testosterone at an optimal range.

Prosta Chi can effectively block the 5-alpha reductase enzyme (see Figure 4) so testosterone is not converted to the more harmful DHT. DHT has been implicated in prostate enlargement and hair loss in men.

For men who have high PSA and/or an enlarged prostate, the risk for prostate cancer is higher. Myomin with Angiostop is recommended in this case.

CASE 1: Estradiol reduced, Testosterone increased, HbA1c reduced, Weight Loss

Take this case, for example. I. Fox, MD from IN, has a 54 y/o/m patient who took Myomin for about 2 years with excellent results. His estradiol reduced and testosterone increased (Table 5). He has also lost weight (275 to 240 lbs). His HbA1c level, a sign of insulin resistance, which is also an estrogen-dominant condition, also reduced. He still continues taking Myomin for maintenance.











CASE 2: Myomin should be added when on BHRT

This case shows that, if not blocked, hyperaromatization of testosterone to estradiol can occur. J. Wright, MD from WA, has a male patient on daily 75mg testosterone therapy, which caused an increase in estradiol. Within 2 months of taking Myomin, hyperaromatization was corrected and his abnormal estradiol level was within normal range (Table 6).









CASE 3: PSA and Weight reduced with Myomin, Angiostop, etc.

Another case shows how PSA and weight reduced with Myomin, Angiostop and other supplements. Dino F. is a 51 y/o/m from FL who started weekly testosterone injections at age 47 in 2013. His testosterone was 350 and PSA was 3. After a year, his testosterone shot up to 1400 and his PSA to 5.9. He was diagnosed with prostate cancer. He took Angiostop, Myomin, Revivin, Asparagus Extract, and Prosta Chi for 2 ½ years. At age 51, his PSA has reduced to 2.8 and he also lost 78 lbs (Table 7).

A couple of years ago, the FDA has warned men about the use of testosterone (T) therapy because it increases heart attack and stroke risk. In one study on 55,593 men on testosterone therapy for 90 days, the risk for heart attack is increased even among men with no history of cardiovascular disease (CVD) (Source: PLoS ONE. 2014;9(1): e85805). Looking at the results (Table 8), men over the age of 65 have 2 times the risk of heart attack whether they have a history of CVD or not.











In addition, another study on 8,709 men with low testosterone and who had been on T therapy for 3 years found a 29% increased risk for stroke, heart attack or death with or without history or coronary artery disease ( JAMA. 2013; 310(17):1829-1836).

Researchers theorize that the increased cardiovascular risks involved with T therapy may be due to testosterone itself which can increase platelet aggregation, a factor in plaque formation. Also testosterone is converted to its metabolite, DHT (see Figure 4), which can increases expression of vascular cell adhesion molecule and contribute to atherosclerosis.

Further research though reveals that the cardiovascular risks involved with T therapy may also be due to the increase in estradiol that is associated with its hyperaromatization (see Figure 4). Testosterone is converted to estradiol through the aromatase enzyme, so T therapy can lead to estrogen dominance. In the last newsletter, we already discussed how excess estradiol causes blood clots and increases the risk of cardiac arrest and heart disease in women. This is most l0ikely the underlying reason for the similar risks that the FDA is warning men about. There is ample evidence showing the association between excess estradiol and cardiovascular disease risk. So men on T therapy must add Myomin in order to counteract the unwanted effects.

HIGH ESTRADIOL DOUBLES THE STROKE RISK

Studies show that men whose estradiol levels were over 34.1 pg/mL had more than twice the risk of stroke compared with those whose estradiol levels were lower (Neurology. 2007; 68(8):563-8). This is why ideally men should have an estradiol level of less than 30 pg/mL.

Earlier we mentioned that cherry angiomas on the head or forehead area indicate a strong risk for stroke or aneurysm. If you see this marker, check CRP and homocysteine levels. CRP should be ideally under 1.0 and homocysteine should be around 6.0.

We see this correlation of high estrogen and stroke in the following case

J. C., a 62 y/o/m, has a cherry angioma right below his eye (Figure 5), indicating a risk for stroke or aneurysm. He also has no lunulae on his left hand and is missing a lunula on his right hand (a sign of poor circulation). His testosterone is low as well. He revealed that did have a stroke in 2001, had open heart surgery in 2009 and has had 9 stents.

HEART ATTACK AND ATHEROSCLEROSIS PATIENTS HAVE HIGH ESTRADIOL 


Numerous studies show that acute heart attack patients, especially men, have significantly higher estradiol levels and low testosterone levels. In fact, in one such study, men who were admitted to the hospital with acute heart attacks had estradiol levels that were 180% higher while their testosterone levels were nearly three times less than those of control patients (Endoc Res. 2002; 28(3): 161-73).

Similarly, atherosclerosis patients have had low testosterone and high estradiol as well as estrone levels ( Int J Cardiol. 2005; 101(1)105-10).

So looking at the case report above, we see that estradiol does have an impact on heart function. The patient is exhibiting signs of estrogen dominance (cherry angiomas) and poor heart function (lack of lunulae). True enough, he did have a history of stroke and heart surgery.

Similarly, the following case illustrates the relationship between estrogen and heart disease.

K.L., 53 y/o/m from CA, is 5’10 and weights 220 lbs. He does have a family history of heart problems. His father had a quadruple bypass and died of a heart attack. So did his uncle. He has had hypertension since 2011 and, despite 3 medications, his blood pressure is still high around 192/116 mmHg. His cholesterol is normal though at 170. He is exhibiting markers of both estrogen dominance and heart problems: cherry angiomas on the head and abdomen (Figures 6 and 7), an earlobe crease (Figure 6), gynecomastia (Figure 7) and edema. Despite a vegetarian and calorie-restricted diet starting in 2012, he has not been able to lose weight. This is because he is estrogen-dominant. Now he is on Myomin.

Men who exhibit both markers for estrogen dominance and heart problems should control their estrogen level and improve heart function. Testosterone therapy should be stopped, if possible. If not, be sure to add Myomin.

To help improve heart function, take VEIN LITE, OXYPOWER and ASPARAGUS EXTRACT.

For more information on cardiovascular disease, please read our March 2017 newsletter.

J. Fowler from FL has a male client who had high PSA at 4.8. After a few months on Angiostop, Myomin and Prosta Chi, his PSA reduced to 2.6 (Table 9). He also has high homocysteine (14.7) so he is taking Vein Lite, Asparagus Extract.

These statements have not been evaluated by the Food & Drug Administration.
These products are not intended to diagnose, prevent, treat or cure any disease.

www.chi-health.com